title: Hypoxic preconditioning increases survival and angiogenic potency of peripheral blood mononuclear cells via oxidative stress resistance.
abstract: Cell-based angiogenesis is a promising treatment for ischemic diseases; however, the survival of implanted cells is impaired by oxidative stress in the ischemic microenvironment. We tested the hypothesis that hypoxic preconditioning of implanted cells enhances their resistance against oxidative stress, increasing cell survival and angiogenic potency after implantation into ischemic tissue. Mouse peripheral blood mononuclear cells (PBMNCs) were collected and subjected to hypoxic preconditioning by culture for 24 h in 2% O(2) at 33 degrees C. Hypoxic preconditioning of PBMNCs increased the expression of various genes related to antioxidant and survival signals remarkably. Compared with cells cultured under normoxia, the hypoxia-preconditioned PBMNCs showed significantly lower reactive oxygen species (ROS) accumulation and higher cell survival under oxidative stress induced by LY-83583 (a superoxide generator). Three days after intramuscular implantation into the ischemic hindlimbs of mice, survival of the hypoxia-preconditioned PBMNCs was high, whereas that of the normoxia-cultured PBMNCs was relatively low. Furthermore, 28 days after treatment microvessel density and blood flow in the ischemic hindlimbs were significantly better in the mice implanted with hypoxia-preconditioned PBMNCs than in those implanted with normoxia-cultured PBMNCs. Hypoxic preconditioning increased the survival and angiogenic potency of PBMNCs, through oxidative stress resistance mechanisms.
authors.affiliation: Department of Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Kubo
authors.forename: Tao-Sheng
authors.initials: TS
authors.lastname: Li
authors.forename: Ryo
authors.initials: R
authors.lastname: Suzuki
authors.forename: Bungo
authors.initials: B
authors.lastname: Shirasawa
authors.forename: Noriyasu
authors.initials: N
authors.lastname: Morikage
authors.forename: Mako
authors.initials: M
authors.lastname: Ohshima
authors.forename: Shu-Lan
authors.initials: SL
authors.lastname: Qin
authors.forename: Kimikazu
authors.initials: K
authors.lastname: Hamano
mesh_terms: D000634:Aminoquinolines / Q000494:pharmacology; D000818:Animals; D002196:Capillaries / Q000502:physiology; D002470:Cell Survival / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015870:Gene Expression / Q000502:physiology; D006162:Guanylate Cyclase / Q000037:antagonists & inhibitors; D006614:Hindlimb / Q000098:blood supply; D000860:Hypoxia / Q000503:physiopathology*; D019157:Ischemic Preconditioning, Myocardial; D051379:Mice; D009000:Monocytes / Q000378:metabolism / Q000502:physiology*; D018919:Neovascularization, Physiologic / Q000502:physiology*; D018384:Oxidative Stress / Q000502:physiology*; D012313:RNA / Q000096:biosynthesis / Q000235:genetics; D017382:Reactive Oxygen Species / Q000378:metabolism; D012039:Regional Blood Flow / Q000502:physiology; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000634:Aminoquinolines; D004791:Enzyme Inhibitors; D017382:Reactive Oxygen Species; D012313:RNA; C041715:6-anilino-5,8-quinolinedione; D006162:Guanylate Cyclase